EUVIMEDEUVIMED entdecken
Crossref

A multimodal anticancer strategy based on exosome-coated prussian blue nanocarriers for melanoma treatment

Ramin Roshani, Mohammad Ramezani, Elnaz Bagheri, Mina Alikhani, Khalil Abnous, Seyed Mohammad Taghdisi, Sahar Taghavi, Fatemeh Kalalinia, Mona Alibolandi

European Journal of Pharmaceutics and Biopharmaceutics · 2027-01 · 230 · 115273

DOI: 10.1016/j.ejpb.2026.115273 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2027-01. Verfasst von Ramin Roshani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Pharmaceutical Research Center, Pharmaceutical Technology Institut…. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overcoming multidrug resistance and tumor recurrence in melanoma requires multimodal therapeutic strategies that surpass the limitations of monotherapy. Herein, we report a biomimetic nanoplatform, HMPB@EX-DOX, designed to combine chemotherapy, photothermal therapy (PTT), and iron-mediated oxidative stress to potentially contribute to ferroptosis-like cell death. The platform is based on hollow mesoporous Prussian blue nanocubes (HMPB), which provide a high specific surface area for doxorubicin (DOX) loading. It is further functionalized with mesenchymal stem cell-derived exosomes (MSC-EX) to enhance biocompatibility and promote tumor accumulation. Under near-infrared (NIR) irradiation, the system induced photothermal heating, chemotherapeutic drug release, and intracellular ROS generation, collectively enhancing oxidative stress in melanoma cells. In vitro clonogenic assays demonstrated that the combined treatment significantly suppressed colony formation to 10.2 ± 1.5%, outperforming single- or dual-modality groups (n = 3, p < 0.001). The biomimetic nanoplatform HMPB@EX-DOX exhibited significant ROS generation in vitro in B16F0 cells, which was enhanced under NIR irradiation. Cellular fluorescence analysis suggested a greater DOX-associated signal in B16F0 cells for HMPB@EX-DOX than for HMPB-DOX. In vivo evaluation in B16F0 melanoma-bearing mice demonstrated significant inhibition of tumor growth. The prepared HMPB@EX-DOX platform exhibited tumor accumulation and photothermal conversion at the tumor site under NIR irradiation. The developed platform was also capable of preclinical MR imaging and showed potential for in vivo contrast enhancement, while histopathological analysis suggested acceptable short-term biosafety of the prepared platform under the tested conditions. Overall, HMPB@EX-DOX represents a promising biomimetic nanoplatform for combined melanoma therapy, offering a useful foundation for future nanomedicine development.

Schlagwörter

Stichwörter der Autor:innen

ExosomeMelanomaOxidative stressPhotothermal therapyPrussian blue nanocubes

Autor:innen und Institutionen

  • Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran; Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department o…
  • Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical S…
  • Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences,…
  • Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Förderung

  • Mashhad University of Medical Sciences

Zitieren

APA

Roshani, R., Ramezani, M., Bagheri, E., Alikhani, M., Abnous, K., Taghdisi, S. M., Taghavi, S., Kalalinia, F., & Alibolandi, M. (2027). A multimodal anticancer strategy based on exosome-coated prussian blue nanocarriers for melanoma treatment. European Journal of Pharmaceutics and Biopharmaceutics, 230, 115273. https://doi.org/10.1016/j.ejpb.2026.115273

Vancouver

Roshani R, Ramezani M, Bagheri E, Alikhani M, Abnous K, Taghdisi SM, et al. A multimodal anticancer strategy based on exosome-coated prussian blue nanocarriers for melanoma treatment. European Journal of Pharmaceutics and Biopharmaceutics. 2027;230:115273. doi:10.1016/j.ejpb.2026.115273

BibTeX
@article{Roshani2027,
  author = {Roshani, Ramin and Ramezani, Mohammad and Bagheri, Elnaz and Alikhani, Mina and Abnous, Khalil and Taghdisi, Seyed Mohammad and Taghavi, Sahar and Kalalinia, Fatemeh and Alibolandi, Mona},
  title = {A multimodal anticancer strategy based on exosome-coated prussian blue nanocarriers for melanoma treatment},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2027},
  volume = {230},
  pages = {115273},
  doi = {10.1016/j.ejpb.2026.115273}
}
Kostenlos starten →